Key Highlights
- Loss per share was USD 0.29 against an estimate of a USD 0.37 loss.
- Research and development expenses were USD 24.7 million, up from USD 22.2 million.
- General and administrative expenses were USD 10.3 million, up from USD 5.7 million.
- Cash and marketable securities are projected to fund operations into the first half of 2029.
Aura Biosciences (NASDAQ:AURA) reported a third quarter 2026 loss per share of USD 0.29, compared with an estimate of a USD 0.37 loss.
Research and development expenses increased to USD 24.7 million from USD 22.2 million in the third quarter of 2025, which the filing attributes to ongoing clinical activity. For the nine months, Research and Development expenses were USD 83.5 million, against USD 68.4 million a year earlier.
Restructuring and Administrative Costs
General and administrative expenses increased to USD 10.3 million from USD 5.7 million in the same quarter of 2025, primarily driven by restructuring charges recognized under the company's organizational restructuring during the quarter. The filing states that in August 2026 the board and executive management developed an enterprise-wide restructuring plan intended to streamline the operating plan and organizational structure and to align resources behind its ocular oncology programs.
In connection with the plan, the company incurred restructuring charges of USD 4.5 million, composed of employee termination benefits including severance, continuation of health care benefits and outplacement services.
Net Loss, Cash Use and Runway
For the nine months ended September 30, 2026, net cash used in Operating Activities was USD 88.8 million, driven primarily by a net loss of USD 111.4 million, partially offset by stock-based compensation expense. In the same period of 2025, net cash used in operating activities was USD 64.3 million and the net loss was USD 80.6 million.
The filing's risk disclosures state that the company has incurred significant net losses since its inception and anticipates continuing to incur losses for the foreseeable future. It also states that its existing cash, cash equivalents and marketable securities are sufficient to fund operations into the first half of 2029, based on its current operating plan.
License Agreements
The filing describes an exclusive license and Supply agreement with LI-COR, entered into in January 2014 and amended several times, for IRDye 700DX, whose licensed Patent is now expired, in the treatment and diagnosis of ocular cancers in humans, as well as a non-exclusive license agreement from December 2014 for non-ocular solid tumor cancers. The company also holds an office and laboratory Lease in Boston, Massachusetts with an initial 10-year term entered into in May 2022. The lease includes one renewal option for an additional seven years, which the company has not deemed probable of being exercised as of September 30, 2026. The restructuring plan was approved by the Board of Directors and executive management.
Aura Biosciences Q3 2026 Earnings: Key Takeaways
Aura Biosciences reported a third quarter 2026 loss per share of USD 0.29, research and development expenses of USD 24.7 million and general and administrative expenses of USD 10.3 million. The company recorded USD 4.5 million of restructuring charges and stated that its cash and marketable securities fund operations into the first half of 2029.
_11_16_2026_19_56_26_124029.jpg)





Please wait processing your request...